目的 探討香連片聯(lián)合美沙拉嗪治療慢性潰瘍性結(jié)腸炎的臨床療效。方法 選取2020年2月—2020年11月在天津醫(yī)科大學(xué)總醫(yī)院治療的104例慢性潰瘍性結(jié)腸炎患者，根據(jù)用藥的差別分為對照組和治療組，每組各52例。對照組口服美沙拉嗪腸溶片，0.5 g/次，3次/d。治療組在對照組基礎(chǔ)上口服香連片，1.5 g/次，3次/d。兩組均經(jīng)3個(gè)月治療進(jìn)行效果對比。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時(shí)間，IBDQ、SAS和Mayo評分，炎癥介質(zhì)C反應(yīng)蛋白（CRP）、白細(xì)胞介素-8（IL-8）、白細(xì)胞介素-33（IL-33）和腫瘤壞死因子-α（TNF-α）水平，及腸道功能屏障。結(jié)果 經(jīng)治療，對照組和治療組臨床有效率分別為82.69%和98.08%，對照組明顯低于治療組（P<0.05）。經(jīng)治療，治療組癥狀改善時(shí)間明顯早于對照組（P<0.05）。經(jīng)治療，兩組IBDQ評分明顯升高，而SAS和Mayo評分顯著降低（P<0.05），且治療組明顯好于對照組（P<0.05）。經(jīng)治療，兩組血清CRP、IL-8、IL-33、TNF-α水平均明顯下降（P<0.05），且治療組更顯著（P<0.05）。經(jīng)治療，兩組D-乳酸、二胺氧化酶、內(nèi)毒素水平均顯著下降（P<0.05），且治療組更明顯（P<0.05）。結(jié)論 香連片聯(lián)合美沙拉嗪治療慢性潰瘍性結(jié)腸炎可有效改善患者臨床癥狀和疾病活動(dòng)程度，降低機(jī)體炎癥反應(yīng)，促進(jìn)腸道屏障功能的恢復(fù)，促進(jìn)患者生活質(zhì)量提高。

Objective To explore the clinical efficacy of Xianglian Tablets combined with mesalazine in treatment of chronic ulcerative colitis. Methods Patients (104 cases) with chronic ulcerative colitis in Tianjin Medical University General Hospital from February 2020 to November 2020 were divided into control and treatment groups based on different treatments, and each group had 52 cases. Patients in the control group were po administered with Mesalazine Enteric Coated Tablets, 0.5 g/time, three times daily. Patients in the treatment group were po administered with Xianglian Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, IBDQ, SAS and Mayo scores, the inflammatory mediators CRP, IL-8, IL-33 and TNF-α, and the intestinal functional barrier in two groups before and after treatment were compared. Results After treatment, the clinical effective rates in the control group and the treatment group were 82.69% and 98.08% respectively, and which in the control group was significantly lower than that in the treatment group (P < 0.05). After treatment, the improvement time of symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, IBDQ scores in two groups were significantly increased, while SAS and Mayo scores were significantly decreased (P < 0.05), and these scores in the treatment group was significantly better than those in the control group (P < 0.05). After treatment, the serum CRP, IL-8, IL-33 and TNF-α levels in two groups were significantly decreased (P < 0.05), and which in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the contents of D-lactate, diamine oxidase and endotoxin in two groups were significantly decreased (P < 0.05), and the decreasing ion the treatment group was the most obvious (P < 0.05). Conclusion Xianglian Tablets combined with mesalazine in treatment of chronic ulcerative colitis can effectively improve the clinical symptoms and disease activity of patients, reduce the body inflammatory reaction, promote the recovery of intestinal barrier function, and improve the quality of life of patients.

R975

天津市教委科研計(jì)劃項(xiàng)目（2018KJ059）